NL2017982B1 - A method of performing an assay - Google Patents
A method of performing an assay Download PDFInfo
- Publication number
- NL2017982B1 NL2017982B1 NL2017982A NL2017982A NL2017982B1 NL 2017982 B1 NL2017982 B1 NL 2017982B1 NL 2017982 A NL2017982 A NL 2017982A NL 2017982 A NL2017982 A NL 2017982A NL 2017982 B1 NL2017982 B1 NL 2017982B1
- Authority
- NL
- Netherlands
- Prior art keywords
- substrate
- wells
- assay
- cell
- cells
- Prior art date
Links
Abstract
Description
OctrooicentrumPatent center
Nederland (21) Aanvraagnummer: 2017982 © Aanvraag ingediend: 12/12/2016The Netherlands (21) Application number: 2017982 © Application submitted: 12/12/2016
Θ 2017982Θ 2017982
BI OCTROOI (51) Int. CL:BI PATENT (51) Int. CL:
B01L 3/00 (2017.01) G01N 33/50 (2017.01)B01L 3/00 (2017.01) G01N 33/50 (2017.01)
© A method of performing an assay (57) A method of performing an assay for a compound using a device comprising with a plurality of wells, and liquid is transferred liquid from the wells to a substrate, which substrate is used to perform the assay.© A method of performing an assay (57) A method of performing an assay for a compound using a device including a variety of wells, and liquid is transferred liquid from the wells to a substrate, which substrate is used to perform the assay.
The method is performed using a device wherein each well comprises a bottom provided with a through-hole extending from the well to the backside of the device. Liquid containing the compound is transferred via the through-holes to the substrate.The method is performed using a device each well comprises a bottom provided with a through-hole extending from the well to the backside of the device. Liquid containing the compound is transferred through the through-holes to the substrate.
Preferably a cell is present in a well and compound excreted by the cell in the well is detected.Preferably a cell is present in a well and compound detected by the cell in the well has been detected.
NL BI 2017982NL BI 2017982
Dit octrooi is verleend ongeacht het bijgevoegde resultaat van het onderzoek naar de stand van de techniek en schriftelijke opinie. Het octrooischrift wijkt af van de oorspronkelijk ingediende stukken. Alle ingediende stukken kunnen bij Octrooicentrum Nederland worden ingezien.This patent has been granted regardless of the attached result of the research into the state of the art and written opinion. The patent differs from the documents originally submitted. All submitted documents can be viewed at the Netherlands Patent Office.
A method of performing an assayA method of performing an assay
The present invention relates to a method of performing an assay for a compound using a device, wherein the device comprisesThe present invention relates to a method of performing an assay for a compound using a device, the device comprises
- a frontside with a plurality of wells, and- a frontside with a variety of wells, and
- a backside;- a backside;
said method comprising the steps ofsaid method including the steps of
- transferring liquid from the wells to the substrate, and- liquid transfer ring from the wells to the substrate, and
- using the substrate to perform the assay.- using the substrate to perform the assay.
A method of performing an assay is disclosed by Christopher Love in A microengraving method for rapid selection of single cells producing antigen-specific antibodies (Nature Biotechnology, 2006, vol. 24(6) p. 703). In this method an assay is performed using a device comprising a plurality of wells, wherein the content (supernatant) of all the wells is transferred simultaneously to a substrate (glass plate), which substrate is used for the assay.A method of performing an assay is disclosed by Christopher Love in A microengraving method for rapid selection of single cell producing antigen-specific antibodies (Nature Biotechnology, 2006, vol. 24 (6) p. 703). In this method an assay is performed using a device including a variety of wells, containing the content (supernatant) or all the wells is transferred simultaneously to a substrate (glass plate), which substrate is used for the assay.
It is an object of the present invention to provide an alternative method according to the preamble.It is an object of the present invention to provide an alternative method according to the preamble.
To this end, a method according to the preamble is characterized in that each well of the plurality of wells comprises a bottom provided with a through-hole extending from the well to the backside of the device, wherein the through-holes have smaller dimensions than cells in the plurality of wells so as to retain the cells physcially in the wells;To this end, a method according to the preamble is characterized in that each well or the multiple of wells comprises a bottom provided with a through-hole extended from the well to the backside of the device, the through-holes have smaller dimensions than cells in the various of wells so as to retain the cells physically in the wells;
wherein the method comprises the steps ofthe method comprises the steps of
- arranging cells in the device, and the compound is excreted by the cells in the device,- arranging cells in the device, and the compound is excreted by the cells in the device,
- contacting the backside of the device with the substrate,- contacting the backside of the device with the substrate,
- performing the step of transferring liquid from the wells to the substrate by transferring liquid from the wells via the through-holes to the substrate, wherein the compound transferred through the through-holes is adsorbed on the substrate, using specific absorption or a-specific adsorption, and- performing the step of transferring liquid from the wells to the substrate by transferring liquid from the wells through the through-holes to the substrate, the compound transferred through the through-holes is adsorbed on the substrate, using specific absorption or a-specific adsorption, and
- performing the step of performing the assay using the substrate.- performing the step or performing the assay using the substrate.
This is an important application of the method, with a variety of applications, for example selecting high-producing hybridoma cells.This is an important application of the method, with a variety of applications, for example selecting high-producing hybridoma cells.
It has been found that the method allows for the convenient detection of the compound. The risk that a cell is dislodged from the well is reduced as it is not necessary to hold the device upside down. The device is for example a MEMS array, as it allows for a great number of wells (thousands or even millions). The through-hole is typically not capable of letting the cell pass through the through-hole, and thus will typically be of smaller dimensions than the cells in the plurality of wells.It has been found that the method allows for the convenient detection of the compound. The risk that a cell is dislodged from the well is reduced as it is not necessary to hold the device upside down. The device is for example a MEMS array, as it allows for a great number of wells (thousands or even millions). The through-hole is typically not capable of letting the cell pass through the through-hole, and thus will typically be smaller or narrower than the cells in the multiple of wells.
At least a part of the plurality of wells contains at least one cell. The cells are typically eukaryotic cells, such as a mammalian cell. It may be an immortal cell (which term includes an immortalised cell), or non-immortal cell.At least a part of the multiple of wells contains at least one cell. The cells are typically eukaryotic cells, such as a mammalian cell. It may be an immortal cell (which term includes an immortalized cell), or non-immortal cell.
The liquid comprising the compound excreted by a cell is commonly referred to as supernatant. In the method according to the invention, the liquid flowing from the well passes the cell, which is hence in contact with medium during this step of the procedure and thus isn't cut off from medium during this step. It is conceivable that there is a layer of fresh medium on top of the device during this step.The liquid containing the compound excreted by a cell is commonly referred to as supernatant. In the method according to the invention, the liquid flowing from the well passes the cell, which is then in contact with medium during this step of the procedure and thus is not cut off from medium during this step. It is conceivable that there is a layer of fresh medium on top of the device during this step.
It has been found that the method allows for the convenient detection of the compound. It is not necessary to hold the device upside down. The device is for example a MEMS array. The through-hole allows for transfer of liquid containing the compound to a spot of relatively small size, in particular smaller than the surface area of the well in the main plane of the device.It has been found that the method allows for the convenient detection of the compound. It is not necessary to hold the device upside down. The device is for example a MEMS array. The through-hole allows for transfer of liquid containing the compound to a spot or relatively small size, in particular narrower than the surface area or the well in the main plane of the device.
The compound is advantageously a compound excreted by a cell.The compound is advantageously a compound excreted by a cell.
The compound is excreted by the cells in the device, following which the step of performing the assay using the substrate is performed.The compound is excreted by the cells in the device, following which the step of performing the assay using the substrate is performed.
The compound is typically an organic compound, such as a metabolite, or a protein.The compound is typically an organic compound, such as a metabolite, or a protein.
The substrate will typically have a planar side for contacting the backside of the device, and in general will be a planar substrate, such as a sheet of material.The substrate will typically have a planar side for contacting the backside of the device, and in general will be a planar substrate, such as a sheet of material.
While the assay may be of any type, including a radioactive tracer-based assay, it is convenient if the assay is some type of optical assay, such as a chemiluminescence-based assay, a fluorescence-based assay or enzyme-based assay where the enzyme effects a change in color (or fluorescence).While the assay may be of any type, including a radioactive tracer-based assay, it is convenient if the assay is some type of optical assay, such as a chemiluminescence-based assay, a fluorescence-based assay or enzyme-based assay where the enzyme effects a change in color (or fluorescence).
Typically the compound transferred through the through-holes will be adsorbed on the substrate, using specific absorption or a-specific adsorption as desired.Typically the compound transferred through the through-holes will be adsorbed on the substrate, using specific absorption or a-specific adsorption as desired.
It has been found that the method according to the invention can be performed with relatively little manual labor.It has been found that the method according to the invention can be performed with relatively little manual labor.
It has also been found that the assay can be performed in little time, such as in 2 hours or less.It has also been found that the assay can be performed in little time, such as in 2 hours or less.
According to a favourable embodiment, performing the assay comprises removing the substrate.According to a favorite embodiment, performing the assay comprises removing the substrate.
According to a favourable embodiment, at least 10% of the plurality of wells contain a single cell.According to a favorite embodiment, at least 10% of the multiple of wells contain a single cell.
Thus it is possible to screen a large number of cells and determine their individual characteristic with respect to the compound measured using the assay. It is known in the art to prepare an array of wells with the wells containing a single cell, for example from EP2855020. The inventor has realised that the restricted flow of liquid through the through-hole can still be used for an assay. In contrast to the method according of Love, the risk that the cell in a well is transferred to the substrate and is lost is reduced, as the device does not need to be held upside down, and also the risk of cross-contamination can be reduced as the closest distance between supernatants from two adjacent wells transferred to the substrate is greater. In addition, the risk of the cell contacting a reagent involved in the assay is reduced.Thus it is possible to screen a large number of cells and determine their individual characteristic with respect to the compound measured using the assay. It is known in the art to prepare an array of wells with the wells containing a single cell, for example from EP2855020. The inventor has realized that the restricted flow or liquid through the through-hole can still be used for an assay. In contrast to the method according to Love, the risk that the cell is in a well is transferred to the substrate and is lost is reduced, as the device does not need to be held upside down, and also the risk of cross-contamination can be reduced as the closest distance between supernatants from two adjacent wells transferred to the substrate is greater. In addition, the risk of the cell contacting a reagent involved in the assay is reduced.
According to a favourable embodiment, the through-hole has dimensions that do not allow the cell to pass through the through-hole .According to a favorite embodiment, the through-hole has dimensions that do not allow the cell to pass through the through-hole.
Thus the cell is physically retained in the well, allowing it to be available for further use, such as for a further assay. It also ensures that the cell does not contact the device.Thus the cell is physically retained in the well, allowing it to be available for further use, such as for a further assay. It also ensures that the cell does not contact the device.
Generally speaking for a device according to the invention suitable for performing an assay on an eukaryotic cell, typical dimensions of the through-hole are 5 pm or smaller in at least one dimension parallel to the backside of the device and preferably less than 3 pm. Preferably these values go for both dimensions parallel to the backside of the device.Generally speaking for a device according to the invention suitable for performing an assay on an eukaryotic cell, typical dimensions of the through-hole are 5 pm or narrower in at least one dimension parallel to the backside of the device and preferably less than 3 pm. Preferably these values go for both dimensions parallel to the backside of the device.
According to a favourable embodiment, the assay is an immunoassay.According to a favorite embodiment, the assay is an immunoassay.
An immunoassay allows a great variety of compounds to be detected. The immunuoassay may be of any type, such as a sandwich assay. It has been found that the method according to the present invention is capable of determining proteins such as antibodies in an amount of less than 1 ng.An immunoassay allows a great variety of compounds to be detected. The immunoassay may be of any type, such as a sandwich assay. It has been found that the method according to the present invention is capable of determining proteins such as antibodies in an amount or less than 1 ng.
According to an especially preferred embodiment, the substrate comprises a micro-porous substrate.According to an especially preferred embodiment, the substrate comprises a micro-porous substrate.
More liquid from the wells can be introduced, allowing a greater sensitivity. It also allows for the compound to be absorbed in a volume that is relatively compact, enhancing the sensitivity even more. Furthermore, the average diffusion distance is small, allowing the method according to the present invention to be relatively quick. According to a preferred embodiment, the substrate allows for a greater rate of transport of liquid in a direction transverse to the main plane of the substrate than in a direction parallel to the main plane. This helps to avoid cross-contamination and to keep the compound from a particular well with in more localised area of the substrate. In contrast, the method of Love would not allow for the use of micro-porous substrate as the adjacent supernatants would contact each other and/or cells would be devoid of medium during the overnight incubation.More liquid from the wells can be introduced, allowing a greater sensitivity. It also allows for the compound to be absorbed in a volume that is relatively compact, enhancing the sensitivity even more. Furthermore, the average diffusion distance is small, allowing the method according to the present invention to be relatively quick. According to a preferred embodiment, the substrate allows for a greater rate of transport or liquid in a direction transverse to the main plane or the substrate than in a direction parallel to the main plane. This helps to avoid cross-contamination and to keep the compound from a particular well with more localized area of the substrate. In contrast, the method of Love would not allow for the use of micro-porous substrate as the adjacent supernatants would contact each other and / or cells would be devoid or medium during the overnight incubation.
The substrate is for example glassfiber, paper, or nitrocellulose.The substrate is for example glass fiber, paper, or nitrocellulose.
Typically, the pores of the micro-porous substrate will be between 0.05 pm and 10 pm, preferably between 0.2 pm and 2 pm.Typically, the pores of the micro-porous substrate will be between 0.05 pm and 10 pm, preferably between 0.2 pm and 2 pm.
According to a favourable embodiment, the liquid is transferred usinq a pressure difference with a relatively low pressure at a side of the substrate opposite of the device.According to a favorite embodiment, the liquid is transferred usinq a pressure difference with a relatively low pressure on a side of the substrate opposite of the device.
The pressure may for example be achieved by increasing the air pressure at the front side of the device. In addition or alternatively, suction may be applied in any suitable manner, e.g. using reduced pressure (vacuum) at the backside of the substrate or by using an absorbing pad in contact with the backside of substrate.The pressure may for example be achieved by increasing the air pressure on the front side of the device. In addition or alternatively, suction may be applied in any suitable manner, e.g., using reduced pressure (vacuum) at the backside of the substrate or by using an absorbing pad in contact with the backside of substrate.
According to a favourable embodiment, the substrate is a polymer, preferably a polymer chosen from i) polyvinylidene difluoride, and ii) nitrocellulose .According to a favorite embodiment, the substrate is a polymer, preferably a polymer selected from i) polyvinylidene difluoride, and ii) nitrocellulose.
These substrates are very well suited for assays, in particular optical assays and immunoassays. Currently polyvinylidene difluoride is most preferred. It is in particular preferred that the polymer substrate is a micro-porous polymer.These substrates are very well suited for assays, in particular optical assays and immunoassays. Currently polyvinylidene difluoride is most preferred. It is particularly preferred that the polymer substrate is a micro-porous polymer.
According to a favourable embodiment, the device comprises a frontside with the plurality of wells and a backside, the backside comprising a plurality of protruding capillaries, the capillaries running transverse to the main plane of the substrate.According to a favorite embodiment, the device comprises a frontside with the various of wells and a backside, the backside including a variety of protruding capillaries, the capillaries running transverse to the main plane of the substrate.
This helps to reduce spreading of the supernatant in a direction parallel to the backside of the device. The compound remains more localized on the substrate, rendering it easier to detect.This helps to reduce spreading of the supernatant in a direction parallel to the backside of the device. The compound remains more localized on the substrate, rendering it easier to detect.
According to a favourable embodiment, the backside of the device is a hydrophobic backside.According to a favorite embodiment, the backside of the device is a hydrophobic backside.
This helps to prevent the flow of liquid emanating from a through-hole sideways. The backside may for example have been provided with a hydrophobic coating, or may have been chemically treated to render it hydrophobic. If the device is a silicon-based device, it may for example be treated with tetramethyl-silane.This helps to prevent the flow of liquid emanating from a through-hole sideways. The backside may have been provided with a hydrophobic coating, or may have been chemically treated to render it hydrophobic. If the device is a silicon-based device, it may be treated with tetramethyl silane for example.
According to a favourable embodiment, the compound is an antibody .According to a favorite embodiment, the compound is an antibody.
This is an important field of application.This is an important field of application.
According to a favourable embodiment, the cell is selected.According to a favorite embodiment, the cell is selected.
The selected cell may be used for a variety of purposes.The selected cell may be used for a variety of purposes.
According to a favourable embodiment, the selected cell is propagated.According to a favorite embodiment, the selected cell is propagated.
Thus advantage can be taken from the properties of the cell selected using the assay.Thus advantage can be tasks from the properties of the cell selected using the assay.
According to a favourable embodiment, the selected cell contains a poly nucleic acid sequence and the method comprises at least one further step chosen from i) multiplication of the poly nucleic acid sequence, ii) determining the nucleotide sequence of the poly nucleic acid sequence, and iii) isolating the poly nucleic acid sequence.According to a favorite embodiment, the selected cell contains a poly nucleic acid sequence and the method comprises at least one further step chosen from i) multiplication of the poly nucleic acid sequence, ii) determining the nucleotide sequence of the poly nucleic acid sequence, and iii) isolating the poly nucleic acid sequence.
Such a further step is important for valorisation of the method according to the invention.Such a further step is important for valorisation or the method according to the invention.
The invention will now be illustrated with reference to the example section below, and with reference to the drawing whereinThe invention will now be illustrated with reference to the example section below, and with reference to the drawing
Fig. 1 shows a photograph of a model experiment for estimating minimal sensitivity achievable by the method according to the invention;FIG. 1 shows a photograph or a model experiment for estimating minimal sensitivity achievable by the method according to the invention;
Fig. 2 shows a photograph of an experiment demonstrating the feasibility of transfer of fluorescently labeled antibody from a microsieve onto a PVDF membrane; andFIG. 2 shows a photograph of an experiment demonstrating the feasibility of transfer or fluorescently labeled antibody from a microsive onto a PVDF membrane; and
Fig. 3A to Fig. 30 schematically shows a method of manufacturing a micro-sieve suitable for use in the present invention both in top view and cross-sectional view.FIG. 3A to FIG. 30 schematically shows a method of manufacturing a microsive suitable for use in the present invention both in top view and cross-sectional view.
Firstly an envisaged method of manufacturing a micro-sieve 390 (Fig. 30) suitable for use in the present invention will be described, which micro-sieve 390 has capillaries 360' (tubes) protruding from the backside of the device 390.Firstly an envisaged method of manufacturing a micro-sieve 390 (Fig. 30) suitable for use in the present invention will be described, which micro-sieve 390 has capillaries 360 '(tubes) protruding from the backside of the device 390.
Single crystal silicon can used as a main structural material for the membrane .Single crystal silicon can be used as a main structural material for the membrane.
Fabrication steps;Fabrication steps;
Fig. 3A. The process starts with a silicon wafer 300. A {100) silicon wafer is preferential because in that case wet anisotropic etching can be used to release the membrane.FIG. 3A. The process starts with a silicon wafer 300. A {100) silicon wafer is preferential because in that case anisotropic etching can be used to release the membrane.
Fig. 3B. Deposition of a silicon nitride layer 310 using Low Pressure Chemical Vapor Deposition (LPCVD).FIG. 3B. Deposition of a silicon nitride layer 310 using Low Pressure Chemical Vapor Deposition (LPCVD).
Fig. 3C. Patterning of silicon nitride 310 using Reactive Ion Etching (RIE). Here a 3 x 3 matrix is schematically shown, but in practice the matrix is much larger for example 100 x 100. The plurality of wells to be formed is not limited to a particular shape, such as rectangular, although a grid-like placement of the wells is preferred.FIG. 3C. Patterning of silicon nitride 310 using Reactive Ion Etching (RIE). Here a 3 x 3 matrix is shown schematically, but in practice the matrix is much larger for example 100 x 100. The multiple of wells to be formed is not limited to a particular shape, such as rectangular, although a grid-like placement of the wells is preferred.
Fig. 3D. Local Oxidation of Silicon (LOCOS) to form a temporary silicon oxide layer 319.FIG. 3D. Local Oxidation of Silicon (LOCOS) to form a temporary silicon oxide layer 319.
Fig. 3E. Resist patterning, with resist layer 329.FIG. 3E. Resist patterning, with resist layer 329.
Fig. 3F. Selective removal of silicon nitride using RIE.FIG. 3F. Selective removal of silicon nitride using RIE.
Fig. 3G. Deep Reactive Etching of Silicon (DRIE) to form small round holes 330.FIG. 3G. Deep Reactive Etching or Silicon (THREE) to form small round holes 330.
Fig. 3H. Resist removal using O2-ashing and chemical cleaning with 100% HNO3.FIG. 3H. Resist removal using O 2 -ashing and chemical cleaning with 100% HNO 3 .
Fig. 31. Selective removal of silicon oxide of the temporary layer 319 using wet chemical etching in hydrofluoric acid (HF) or buffered HF.FIG. 31. Selective removal of silicon oxide or the temporary layer 319 using wet chemical etching in hydrofluoric acid (HF) or buffered HF.
Fig. 3J. Deep Reactive Etching of Silicon (DRIE) to form cups 340 (wells 340) and at the same time to further deepen the holes 330.FIG. 3J. Deep Reactive Etching or Silicon (THREE) to form cups 340 (wells 340) and at the same time to further deepen the holes 330.
Fig. 3K. Removal of the first silicon nitride layer 310 using HF or hot phosphoric acid (H3PO4) .FIG. 3K. Removal of the first silicon nitride layer 310 using HF or hot phosphoric acid (H 3 PO 4 ).
Fig. 3L. Deposition of a first low stress silicon nitride layerFIG. 3L. Deposition of a first low stress silicon nitride layer
350' (SiRN) and second low stress silicon nitride layer 350 on the backside of the wafer 300 by LPCVD.350 '(SiRN) and second low stress silicon nitride layer 350 on the backside of the wafer 300 by LPCVD.
Fig. 3M. Patterning of the second silicon nitride layer 350 on the backside of the wafer 300 using RIE of silicon nitride.FIG. 3M. Patterning of the second silicon nitride layer 350 on the backside of the wafer 300 using RIE or silicon nitride.
Fig. 3N. Backside etching of silicon in order to form a silicon membrane and expose closed silicon nitride tubes 360. Note that the bottom of the cups 340 is not exposed in this step. For this step wet anisotropic etching of silicon in TMAH may be used. DRIE process could be used as well, alone or in combination with wet anisotropic etching.FIG. 3N. Backside etching or silicon in order to form a silicon membrane and expose closed silicon nitride tubes 360. Note that the bottom of the cups 340 is not exposed in this step. For this step anisotropic etching or silicon in TMAH may be used. THREE process could be used as well, alone or in combination with wet anisotropic etching.
Fig. 30. RIE directional etching of silicon nitride from the backside of the wafer 300 in order to create open capillaries 360' (defining through-holes 370). This is a device 390 suitable for use in the method according to the invention, with a frontside 391 and a backside 392. The through-hole 370 of a capillary 360' connects a well 340 with the backside 392.FIG. 30. RIE directional etching or silicon nitride from the backside of the wafer 300 in order to create open capillaries 360 '(defining through-holes 370). This is a device 390 suitable for use in the method according to the invention, with a frontside 391 and a backside 392. The through-hole 370 or a capillary 360 'connects a well 340 with the backside 392.
Fig. 3P . Backside etching to expose the bottom of the cups 340 in order to make the membrane locally optically transparent, more specifically the (thin) bottoms of the cups 340.FIG. 3P. Backside etching to expose the bottom of the cups 340 in order to make the membrane locally optically transparent, more specifically the (thin) bottoms of the cups 340.
EXAMPLE 1EXAMPLE 1
Spotting experiment for estimating minimal sensitivity (model experiment not according to the invention)Spotting experiment for estimating minimal sensitivity (model experiment not according to the invention)
PVDF (Polyvinylidene difluoride ) membrane (Immun-Blot® low fluorescence PVDF membrane, BioRad Laboratories B.V., Veenendaal, The Netherlands) was activated in methanol and MilliQ according to protocol manufacturer.PVDF (Polyvinylidene difluoride) membrane (Immun-Blot® low fluorescent PVDF membrane, BioRad Laboratories B.V., Veenendaal, The Netherlands) was activated in methanol and MilliQ according to protocol manufacturer.
The PVDF membrane was placed onto filter paper (Bio-Rad, included with the purchased PVDF) wetted in PBS.The PVDF membrane was placed on filter paper (Bio-Rad, included with the purchased PVDF) legalized in PBS.
A rhEpCAM (recombinant human EpCAM protein, ACRO Biosystems, EPM-H5223, Bethesda, MD, USA) dilution series was prepared in PBSA rhEpCAM (recombinant human EpCAM protein, ACRO Biosystems, EPM-H5223, Bethesda, MD, USA) dilution series was prepared in PBS
F) 1 pg/pLF) 1 pg / pL
G) 0 pg/pL pL of each concentration was pipetted manually onto the pretreated PVDF membrane.G) 0 pg / pL pL or each concentration was pipetted manually onto the pretreated PVDF membrane.
After 10 minutes to allow the droplets to be absorbed, the PVDF membrane with spots A) - G) was incubated with 2 mL blocking buffer (PBS, 1% BSA) for 15 minutes.After 10 minutes to allow the droplets to be absorbed, the PVDF membrane with spots A) - G) was incubated with 2 mL blocking buffer (PBS, 1% BSA) for 15 minutes.
Preparation anti-human EpCAM FITC solutionPreparation anti-human EpCAM FITC solution
2,32 pL of anti-human EpCAM FITC (0.43 mg/mL from AcZon, Bologna, Italy) was pipetted into 2,32 mL PBS buffer.2.32 µL or anti-human EpCAM FITC (0.43 mg / mL from AcZon, Bologna, Italy) was pipetted into 2.32 mL PBS buffer.
The blocking buffer was removed and the PVDF membrane was incubated for 15 minutes in 2 mL anti-human EpCAM FITC solution.The blocking buffer was removed and the PVDF membrane was incubated for 15 minutes in 2 mL of anti-human EpCAM FITC solution.
The antibody solution was removed and the PVDF membrane was washed in washing buffer (PBS) for 2x 5 minutes.The antibody solution was removed and the PVDF membrane was washed in washing buffer (PBS) for 2x 5 minutes.
The PVDF strip was viewed under a fluorescence microscope. The spot diameter was 2 mm and a concentration of 1 ng/pl (C) was clearly visible (Fig. 1) while the 100 pg/pl spot was discernible with the eye .The PVDF strip was viewed under a fluorescence microscope. The spot diameter was 2 mm and a concentration of 1 ng / pl (C) was clearly visible (Fig. 1) while the 100 pg / pl spot was discernible with the eye.
The spot diameter in Fig. 1 is 2 mm, i.e. quite large, indicating that the read-out sensitivity for smaller spots with the same fluorescent-protein concentration is below 1 ng. If the diameter of the spots is smaller, then the sensitivity is even well below 1 ng.The spot diameter in FIG. 1 is 2 mm, i.e. quite large, indicating that the read-out sensitivity for smaller spots with the same fluorescent-protein concentration is below 1 ng. If the diameter of the spots is narrower, then the sensitivity is equally well below 1 ng.
EXAMPLE 2EXAMPLE 2
Transfer of fluorescently labeled antibody from a microsieve onto a PVDF membraneTransfer of fluorescently labeled antibody from a microsive onto a PVDF membrane
Preparation of the devicePreparation of the device
A microsieve was de-aerated in methanol and washed with MilliQ. The microsieve was obtained from VyCap BV (Deventer, The Netherlands) and used without the plastic holder it is sold in. The microsieve has through-holes with a diameter of 5 pm.A microsieve was de-aerated in methanol and washed with MilliQ. The microsive was obtained from VyCap BV (Deventer, The Netherlands) and used without the plastic holder. The microsive has through holes with a diameter of 5 µm.
PVDF membrane preparationPVDF membrane preparation
PVDF (Polyvinylidene difluoride ) membrane (0.20 pm pore size, Immun-Blot® low fluorescence PVDF membrane, BioRad Laboratories B.V., Veenendaal, The Netherlands) was activated in methanol and MilliQ according to protocol manufacturer.PVDF (Polyvinylidene difluoride) membrane (0.20 pm porous size, Immun-Blot® low fluorescence PVDF membrane, BioRad Laboratories B.V., Veenendaal, The Netherlands) was activated in methanol and MilliQ according to protocol manufacturer.
Transfer of fluorescently labelled antibody to the PVDF membraneTransfer of fluorescently labeled antibody to the PVDF membrane
The microsieve without holder was placed onto a wet PVDF membrane floating on MilliQ in a Petri dish. (In another experiment, the microsieve was placed onto filter paper (Bio-Rad, included with the purchased PVDF wetted in MilliQ) which also worked).The microsieve without holder was placed on a PVDF membrane floating on MilliQ in a Petri dish. (In another experiment, the microsive was placed on filter paper (Bio-Rad, included with the purchased PVDF legalized in MilliQ) which also worked).
pL anti-IgG PE (Sigma-Aldrich, P8547, 0.1-0.3 pg/pL, diluted 1:20, phycoerythrin labeled) was pipetted onto the microsieve.pL anti-IgG PE (Sigma-Aldrich, P8547, 0.1-0.3 pg / pL, diluted 1:20, phycoerythrin labeled) was pipetted onto the microsive.
The microsieve was removed by lifting it vertically and the PVDF membrane was imaged under a fluorescence microscope. It was found that the solution was successfully passed through the microsieve and tiny fluorescent spots were visible. These spots had a diameter of about 40 pm.The microsive was removed by lifting it vertically and the PVDF membrane was imaged under a fluorescence microscope. It was found that the solution was successfully passed through the microsive and tiny fluorescent spots were visible. These spots had a diameter of about 40 µm.
EXAMPLE 3EXAMPLE 3
Assay of single hybridomas cells producing an antibody against an antigen on antigen-coated PVDF (according to the invention)Assay of single hybridomas cells producing an antibody against an antigen on antigen-coated PVDF (according to the invention)
PVDF membrane preparationPVDF membrane preparation
Activation step: Activate the micro-porous PVDF membrane in methanol and MilliQ according to protocol manufacturer. The PVDF membrane with a pore size of 0.45 pm was Immun-Blot® low fluorescence PVDF membrane (BioRad Laboratories B.V., Veenendaal, The Netherlands).Activation step: Activate the micro-porous PVDF membrane in methanol and MilliQ according to protocol manufacturer. The PVDF membrane with a porous size of 0.45 µm was Immun-Blot® low fluorescent PVDF membrane (BioRad Laboratories B.V., Veenendaal, The Netherlands).
Coating step: Apply 500 pL 10 ng/pL antigen on PVDF and incubate for 15 minutes.Coating step: Apply 500 pL 10 ng / pL antigen on PVDF and incubate for 15 minutes.
Blocking step: Incubate PVDF 15 minutes in PBS, 1% BSA.Blocking step: Incubate PVDF 15 minutes in PBS, 1% BSA.
Preparation of devicePreparation of device
The microsieve suitable for use in these experiments can be obtained from VyCap BV (Deventer, The Netherlands) and its plastic holder will be removed for our experiments.The microsive suitable for use in these experiments can be obtained from VyCap BV (Deventer, The Netherlands) and its plastic holder will be removed for our experiments.
This microsieve will be de-aerated in methanol, washed withThis microsive will be de-aerated in methanol, washed with
MilliQ in accordance with the protocol of the manufacturer and placed in PBS.MilliQ in accordance with the protocol of the manufacturer and placed in PBS.
Cell loading of the microsieveCell loading of the microsieve
Hybridoma cells can be cultivated in a suitable culture medium (such as Gibco® CD hybridoma, + 4 mM L-Glutamine, + 1% penicillin/streptomycin). Prior to loading the microsieve with the hybridoma cells, the hybridoma cells will be washed to remove the antibody already present in the culture medium. The hybridoma cell suspension will be centrifuged at 300 rpm for 5 minutes. Excess medium will be removed and the cells will be re-suspended in fresh medium at a concentration of approximately 3000 cells in 50 pL medium. The microsieve will be loaded with cells in accordance to the instructions of the manufacturer, with the microsieve being placed on a sponge (Vycap BV). The cell suspension will be pipetted onto the microsieve and, after the cells are sufficiently loaded into the wells, the microsieve may be submerged fully in medium. Excess medium will be removed before further handling of the microsieve.Hybridoma cells can be cultivated in a suitable culture medium (such as Gibco® CD hybridoma, + 4 mM L-Glutamine, + 1% penicillin / streptomycin). Prior to loading the microsive with the hybridoma cells, the hybridoma cells will be washed to remove the antibody already present in the culture medium. The hybridoma cell suspension will be centrifuged at 300 rpm for 5 minutes. Excess medium will be removed and the cells will be re-suspended in fresh medium at a concentration of approximately 3000 cells in 50 pL medium. The microsive will be loaded with cells in accordance with the manufacturer's instructions, with the microsive being placed on a sponge (Vycap BV). The cell suspension will be pipetted onto the microsive and, after the cells are sufficiently loaded into the wells, the microsive may be submerged fully in medium. Excess medium will be removed before further handling of the microsieve.
Transfer of supernatant to the PVDF membraneTransfer of supernatant to the PVDF membrane
Wet filter paper soaked in PBS will be placed in a petridish.Wet filter paper soaked in PBS will be placed in a petridish.
The antigen-coated PVDF membrane will be placed on top of said filter paper taking care that no air is trapped between the filter paper and the membrane.The antigen-coated PVDF membrane will be placed on top of said filter paper taking care that no air is trapped between the filter paper and the membrane.
The microsieve with cells will be placed on the PVDF membrane and allowed to sit overnight in an incubator at 37 °C, 100% humidity, 5% CO2.The microsive with cells will be placed on the PVDF membrane and allowed to sit overnight in an incubator at 37 ° C, 100% humidity, 5% CO 2 .
Incubation with fluorescently labelled anti-antibodyIncubation with fluorescently labeled anti-antibody
After the incubation period the PVDF will be removed and rinsed with PBS (2x 5 minutes) and incubated with 10 ng/pL anti-IgG-PE for 15 minutes. Anti-IgG-PE (Sigma-Aldrich Corp., St. Louis, MO, USA) contains phycoerythrin as a fluorescent label.After the incubation period the PVDF will be removed and rinsed with PBS (2x 5 minutes) and incubated with 10 ng / pL anti-IgG-PE for 15 minutes. Anti-IgG-PE (Sigma-Aldrich Corp., St. Louis, MO, USA) contains phycoerythrin as a fluorescent label.
The PVDF membrane can be examined under a fluorescence microscope. The differences in fluorescence intensity are proportional to the antibody production levels of individual hybridomas cells.The PVDF membrane can be examined under a fluorescence microscope. The differences in fluorescence intensity are proportional to the antibody production levels or individual hybridomas cells.
EXAMPLE 4EXAMPLE 4
Assay of single hybridomas cells producing antibody against the antigen on unmodified PVDF (according to the invention)Assay of single hybridomas cells producing antibody against the antigen on unmodified PVDF (according to the invention)
This experiment can be performed analogous to Example 3 except for the PVDF preparation which will not be coated with the antigen. After contacting the PVDF membrane with the liquid from the wells, the PVDF membrane is blocked, e.g. using the BSA solution and then incubated with the fluorescently labelled anti-antibody.This experiment can be performed analogous to Example 3 except for the PVDF preparation which will not be coated with the antigen. After contacting the PVDF membrane with the liquid from the wells, the PVDF membrane is blocked, e.g. using the BSA solution and then incubated with the fluorescently labeled anti-antibody.
The PVDF membrane can be examined under a fluorescence microscope. Differences in fluorescence intensity are proportional to differences in antibody production levels of individual hybridomas cells .The PVDF membrane can be examined under a fluorescence microscope. Differences in fluorescence intensity are proportional to differences in antibody production levels or individual hybridomas cells.
EXAMPLE 5EXAMPLE 5
Stamping on PVDF (according to the invention)Stamping on PVDF (according to the invention)
Experiment 3 can be continued as follows. After the overnight incubation, the microsieve of Example 3 can be placed for 5 minutes on a freshly prepared PVDF membrane coated with antigen as described in Example 3.Experiment 3 can be continued as follows. After the overnight incubation, the microsive of Example 3 can be placed for 5 minutes on a freshly prepared PVDF membrane coated with antigen as described in Example 3.
Visual examination under a fluorescence microscope can be used to reveal that the fluorescent spots are more localised.Visual examination under a fluorescence microscope can be used to reveal that the fluorescent spots are more localized.
Claims (14)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2017982A NL2017982B1 (en) | 2016-12-12 | 2016-12-12 | A method of performing an assay |
US16/467,661 US20190369090A1 (en) | 2016-12-12 | 2017-12-01 | A Method Of Performing An Assay |
PCT/NL2017/050804 WO2018111096A1 (en) | 2016-12-12 | 2017-12-01 | A method of performing an assay |
EP17835720.8A EP3551763B1 (en) | 2016-12-12 | 2017-12-01 | A method of performing an assay |
KR1020197019970A KR20190095349A (en) | 2016-12-12 | 2017-12-01 | How to do the test |
ES17835720T ES2860474T3 (en) | 2016-12-12 | 2017-12-01 | A procedure for conducting an assay |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2017982A NL2017982B1 (en) | 2016-12-12 | 2016-12-12 | A method of performing an assay |
Publications (1)
Publication Number | Publication Date |
---|---|
NL2017982B1 true NL2017982B1 (en) | 2018-06-29 |
Family
ID=62937170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL2017982A NL2017982B1 (en) | 2016-12-12 | 2016-12-12 | A method of performing an assay |
Country Status (1)
Country | Link |
---|---|
NL (1) | NL2017982B1 (en) |
-
2016
- 2016-12-12 NL NL2017982A patent/NL2017982B1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10335783B2 (en) | Multistep reaction lateral flow capillary device | |
AU666821B2 (en) | Analyte detection device and process | |
US11293922B2 (en) | Sequential lateral flow device | |
JP4705000B2 (en) | Products and processes for immunoassays | |
JP2001525063A (en) | Analyzers for membrane-based assays | |
WO2015175849A1 (en) | Method and apparatus for biomolecule analysis | |
CN104254395A (en) | Sequential lateral flow capillary device for analyte determination | |
TW201839398A (en) | Immunochromatographic device for extracting and measuring carbohydrate antigens | |
US20130252847A1 (en) | Assay assembly and method | |
SE533515C2 (en) | Analysis procedure for simultaneous analysis of several analytes | |
CN110542757A (en) | method for quantitatively detecting bacteria and drug sensitivity experiment by using micro-fluidic chip | |
CN106153891B (en) | Three dimensional biological marker detection device, preparation method and the method for detecting biomarker | |
NL2017982B1 (en) | A method of performing an assay | |
US20110200986A1 (en) | Bio-assay using liquid crystals | |
EP3551763B1 (en) | A method of performing an assay | |
Stephens et al. | Mass-producible microporous silicon membranes for specific leukocyte subset isolation, immunophenotyping, and personalized immunomodulatory drug screening in vitro | |
US10393664B2 (en) | Point-of-care test system and method for applying a sample | |
JPH0755810A (en) | Device and method for detecting body under test | |
JP3640354B2 (en) | Specific binding analysis method and device used therefor | |
US20150369802A1 (en) | Biomolecule Binding Composite Surfaces, Methods Of Making Such Surfaces, Devices Incorporating Such Surfaces, And Methods Of Using Such Surfaces In Biomolecule Binding Assays, And Devices Therefor | |
CN113188959A (en) | Micro-nano biological particle thermophoresis detection device and method | |
JP4273064B2 (en) | Multi-layer analysis element | |
EP1966604A2 (en) | A sensor for biomolecules and a method for preparing and using the same | |
JP2003240784A (en) | Test piece for chromatographic measuring method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD | Change of ownership |
Owner name: MINQ SOLUTIONS B.V.; NL Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: SMARTTIP B.V. Effective date: 20200911 |
|
MM | Lapsed because of non-payment of the annual fee |
Effective date: 20220101 |